CD274 and B-cell non-Hodgkin lymphoma: Regarding B cell lymphomas, promising results were observed with immune checkpoint inhibitors targeting the PD-1/PD-L1 axis in the treatment of classical Hodgkin lymphoma with response rates exceeding 70% (53).